Mruk-Med I Sp. z o.o.

Rzeszow 30 trials 16 recruiting

30 Registered trials

16 Currently recruiting

Organisation

Mruk-Med I Sp. z o.o.

Location

Rzeszow, Poland

Identifier

ORG-100044042

Address

Ul. Gen. Mariana Langiewicza 61, 35-021, Poland

Departments

#2103: Oncology
660: MRUK-MED I Sp. z o.o.
Centrum Medyczne Mruk-Med
Mruk-Med
MRUK-MED I Sp. z o.o.
Mruk-Med I Sp. z o. o.
n/a
NA
Not applicable
Oddzial Onkologii Klinicznej
Oncology
Oncology Clinic
Oncology Department
Onkologia/ Oncology
Poradnia Onkologiczna

Clinical trials at this site (30)

Search interface

A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies … Ended

2024-511646-40-00 First-line (1L) Stage IV Triple Negative Breast Cancer 9 2019-07-11
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Small Cell Lung Cancer (SCLC) 5 2022-07-19
Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Ended

2024-514570-43-00 Renal cell carcinoma 5 2022-01-24
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer Ended

2024-515051-38-00 Non-small Cell Lung Cancer 5 2018-07-20
Efficacy and safety of the proposed biosimilar PERT-IJS versus EU-Perjeta® along with trastuzumab and chemotherapy (carboplatin and docetaxe… Ended

2023-506163-34-00 Hormone Receptor Negative (HR-ve) Human Epidermal Growt 5
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer) Ended

2023-506975-83-00 HER2-positive metastatic breast cancer (MBC) and early 5